17 Hydroxyprogesterone Caporate 17P

A number of studies have shown 17α Hydroxyprogesterone Caporate (17P) therapy in women with a documented history of a previous spontaneous preterm birth to be significantly effective in reducing preterm birth. In an effort to increase physician understanding of 17P and improve the lives of their female patients, ACOG District II has developed medical education materials.

As part of this initiative, a District II taskforce chaired by Dr. Peter Bernstein developed a 17P grand rounds curriculum and provider resource guide.

For more information about the 17P initiative, please contact Kristin Zielinski, Director of Medical Education, at kzielinski@ny.acog.org or (518) 436-3461. 

Resources

Press Release - FDA approves drug to reduce risk of preterm birth in
at-risk pregnant women

Resource Guide - Preventing Preterm Birth: The Role of 17P

ACOG Green Journal 

ACOG Committee Opinion

17P Grand Rounds Curriculum